Medicus Pharma Ltd (MDCX)
NASDAQ:MDCX
MDCX Stock Chart & Stats
$1.46
-$0.29(-9.70%)
At close: 4:00 PM EST
$1.46
-$0.29(-9.70%)
Day’s Range― - ―
52-Week Range$0.37 - $8.94
Previous CloseN/A
Volume5.92K
Average Volume (3M)7.33M
Market Cap
$17.71M
Enterprise Value$7.56M
Total Cash (Recent Filing)$6.35M
Total Debt (Recent Filing)$4.00M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
May 28, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding39,362,110
10 Day Avg. Volume1,663,065
30 Day Avg. Volume7,333,790
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-391.45
Price to Sales (P/S)0.00
P/FCF Ratio-1.16
Enterprise Value/Market Cap0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.23
Forecast
1Y Price Target
$6.00Price Target Upside310.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.51
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Durability And Follow-upExtended patient follow-up could reveal later-onset responses and stronger durability of effect, increasing confidence in the treatment's long-term benefit.
Licensing And Partnership EconomicsA license amendment that materially reduced royalty obligations while preserving global rights improves the asset's attractiveness for future licensing or partnering deals.
Regulatory PathwayAnalyst's Buy rating reflects that exploratory mid-stage data may still support substantive regulatory discussions and shape the design of next development steps.
Bears Say
Dose Strategy And Development RiskPrior mid-stage findings showed strong initial responses but limited durability at the evaluated dose, signaling a need to modify dosing or trial design to mitigate development risk.
Efficacy Signal UncertaintyA placebo microneedle produced tissue results similar to the drug arms, creating doubt about whether the observed effects are attributable to the therapy.
Market Sentiment And Share VolatilityDivergent interpretations of the trial data prompted negative investor reaction, exerting downward pressure on the share price and raising potential for heightened volatility.
Medicus Pharma Ltd News
MDCX FAQ
What was Medicus Pharma Ltd’s price range in the past 12 months?
Medicus Pharma Ltd lowest stock price was $0.37 and its highest was $8.94 in the past 12 months.
What is Medicus Pharma Ltd’s market cap?
Medicus Pharma Ltd’s market cap is $17.71M.
When is Medicus Pharma Ltd’s upcoming earnings report date?
Medicus Pharma Ltd’s upcoming earnings report date is May 28, 2026 which is in 59 days.
How were Medicus Pharma Ltd’s earnings last quarter?
Medicus Pharma Ltd released its earnings results on Mar 25, 2026. The company reported -$0.07 earnings per share for the quarter, the consensus estimate of -$0.07 by $0.
Is Medicus Pharma Ltd overvalued?
According to Wall Street analysts Medicus Pharma Ltd’s price is currently Undervalued.
Does Medicus Pharma Ltd pay dividends?
Medicus Pharma Ltd does not currently pay dividends.
What is Medicus Pharma Ltd’s EPS estimate?
Medicus Pharma Ltd’s EPS estimate is -0.14.
How many shares outstanding does Medicus Pharma Ltd have?
Medicus Pharma Ltd has 39,362,110 shares outstanding.
What happened to Medicus Pharma Ltd’s price movement after its last earnings report?
Medicus Pharma Ltd reported an EPS of -$0.07 in its last earnings report, expectations of -$0.07. Following the earnings report the stock price went down -5.68%.
Which hedge fund is a major shareholder of Medicus Pharma Ltd?
Currently, no hedge funds are holding shares in MDCX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Medicus Pharma Ltd
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets, with an emphasis on non-invasive treatments for skin cancer.
MDCX Stock 12 Month Forecast
Average Price Target
$6.00
▲(310.96% Upside)
Technical Analysis
Ovid Therapeutics
―
Jasper Therapeutics
―
Cognition Therapeutics
―
Neurosense Therapeutics Ltd.
―
PepGen Inc.
―
Ownership Overview
13.79% Insiders
0.01% Mutual Funds
13.57% Other Institutional Investors
72.49% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---